查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807920

生物製藥契約製造市場（按服務類型、產品類型、生產階段、應用和組織規模）—2025-2030 年全球預測

Biopharmaceuticals Contract Manufacturing Market by Service Type, Product Type, Production Stage, Application, Organisation Size - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年生物製藥契約製造市場價值將達212億美元，2025年將成長至231.1億美元，複合年成長率為9.24%，到2030年將達到360.6億美元。

主要市場統計數據
基準年2024年 212億美元
預計2025年 231.1億美元
預測年份 2030 360.6億美元
複合年成長率（%） 9.24%

生物製藥契約製造領域的開創性進展將催生下一代治療開發和供應鏈卓越

生物製藥契約製造正在從一種輔助服務模式演變為創新和加速上市的戰略推動力。隨著從單株抗體到先進細胞和基因療法等治療模式日益複雜，外包合作夥伴已不再只是服務供應商，而是成為製劑、製程最佳化和法規合規的關鍵合作者。這種轉變的驅動力源於先進技術平台的整合、嚴格的品質要求以及整體研發過程中業務靈活性日益成長的需求。

技術進步和策略聯盟推動生物製藥契約製造的典範轉移，推動產業發生前所未有的變革。

生物製藥契約製造製造業正在經歷重大變革，這得益於技術突破、策略聯盟和監管模式的轉變。一次性技術和連續生產方法正在取代傳統的不銹鋼系統，提高生產線的靈活性並縮短週轉時間。人工智慧和高階分析技術正在整合到品管工作流程中，增強預測性維護並確保批次一致性。

全面評估2025年美國關稅對生物製藥契約製造供應鏈和產業動態的影響

2025年美國新關稅的實施對全球生物製藥契約製造供應鏈產生了連鎖反應。從受影響地區進口的原料和關鍵試劑將提高關稅，導致投入成本上升，並對利潤結構造成壓力。受託製造製造商正在透過重新評估其供應商組合、探索近岸外包選項以及重新談判長期供應協議來應對市場波動。

揭示對生物製藥契約製造中服務類型、產品類型、生產階段、應用和組織規模的細分洞察

仔細檢視服務類型、產品類型、生產階段、應用和組織規模，就能發現受託製造領域蘊含的微妙機會與挑戰。分析和品管測試仍然是基礎，但人們越來越重視能夠加速決策的高通量、多屬性方法。生技藥品製造服務正在不斷發展，以支持日益複雜的分子，製程開發和最佳化舉措正構建為並行工作流，從而實現從實驗室規模到中試生產的快速過渡。

揭示美洲、歐洲、中東和非洲以及亞太市場生物製藥契約製造的區域動態

區域動態在塑造外包策略和成本結構方面發揮關鍵作用。美洲地區在合約受託製造能力方面繼續遙遙領先，這得益於其強大的合約製造（CMO）生態系統、監管專業知識和成熟的物流網路。同時，歐洲、中東和非洲地區則受益於豐富的專業科學家人才庫、部分市場優惠的稅收優惠政策，以及強大的產學研合作傳統，這些都促進了早期生物程序創新。

確定塑造全球生物製藥契約製造未來的關鍵創新者和策略合作者

領先的受託製造製造商正憑藉其技術領先地位、不斷擴展的生產能力以及與領先生物製藥公司和新興生物技術創新者的戰略聯盟，脫穎而出。一些供應商正在大力投資一次性生物反應器系統和連續層析法，而另一些供應商則正在利用多屬性質譜和自動採樣技術來增強其分析測試套件。

為行業領導者提供切實可行的策略，推動不斷發展的生物製藥契約製造領域的成長和卓越營運

行業領導者必須採取多管齊下的策略，確保韌性並推動成長。投資整合即時流程監控和預測分析的數位平台，將改善決策並降低批次缺陷的風險。結合模組化設備和一次性技術的彈性製造網路，能夠提供所需的靈活性，以滿足不同臨床階段和治療模式不斷變化的需求。

用於揭示生物製藥契約製造研究中關鍵見解的方法嚴謹性和創新調查方法

分析基於一種混合調查方法，將嚴謹的二手資料研究與一手質性訪談結合。透過廣泛查閱監管指南、行業白皮書和公司特定出版物，我們對技術趨勢和政策變化有了基礎性的了解。二級資訊來源經過可信度審查，並與近期同行評審日誌進行交叉引用，以確保事實準確性。

摘要關鍵發現並綜合見解，為生物製藥契約製造生態系統的策略決策者提供指導

技術敏捷性日益重要、策略夥伴關係關係發揮關鍵作用、貿易政策轉變中供應鏈彈性的必要性等等。這些見解強調了受託製造製造商必須超越傳統的單一產能模式，並轉型為綜合創新合作夥伴。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 一次性生物反應器技術在CDMO設施中的快速擴展，以提高生物製藥生產的靈活性
  • mRNA 疫苗契約製造需求激增，推動全部區域對 CDMO 產能的投資
  • 透過整合連續單株抗體製造流程提高生產效率
  • 在生物製藥 CDMO 中實施高階分析和人工智慧以進行預測流程最佳化
  • 生技公司與CDMO建立策略聯盟，加速細胞與基因治療生產
  • 擴大高效和無菌生技藥品的合約填充和完成服務，以滿足不斷變化的監管要求
  • 為了支持基因治療管道，人們越來越有興趣將病毒載體生產外包給專門的 CDMO。

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：生物製藥契約製造市場（按服務類型）

  • 分析和品管測試
  • 生物製藥製造服務
  • 製程開發與最佳化

第9章生物製藥契約製造市場（依產品類型）

  • 細胞和基因治療
    • CAR-T療法
    • 基因編輯療法
  • 單株抗體
  • 重組蛋白
    • 酵素
    • 荷爾蒙
  • 疫苗
    • mRNA疫苗
    • 蛋白質次單元疫苗
    • 病毒載體疫苗

第 10 章生物製藥契約製造市場（按生產階段）

  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的

第 11 章生物製藥契約製造市場（按應用）

  • 自體免疫疾病
  • 心血管系統
  • 感染疾病
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 神經病學
  • 腫瘤學

第 12 章生物製藥契約製造市場（依公司規模）

  • 大型組織
  • 小型企業

13.美洲生物製藥契約製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章歐洲、中東和非洲生物製藥契約製造市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太生物製藥契約製造市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie, Inc.
    • Ajinomoto Co., Inc.
    • 3P Biopharmaceuticals
    • Aenova Group GmbH
    • AGC Biologics
    • Aurobindo Pharma Limited
    • Boehringer Ingelheim International GmbH
    • Cambrex Corporation
    • Catalent, Inc.
    • Celonic AG
    • FUJIFILM Diosynth Biotechnologies
    • INCOG BioPharma Services, Inc.
    • JRS PHARMA GmbH+Co. KG
    • KBI Biopharma Inc
    • Lonza AG
    • Merck KGaA
    • Pressure BioSciences, Inc. by Emergent Health Corp.
    • ProBioGen AG
    • Rentschler Biopharma SE
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Toyobo Co., Ltd.
    • WuXi Biologics, Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-8C74ADFC15ED

The Biopharmaceuticals Contract Manufacturing Market was valued at USD 21.20 billion in 2024 and is projected to grow to USD 23.11 billion in 2025, with a CAGR of 9.24%, reaching USD 36.06 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 21.20 billion
Estimated Year [2025] USD 23.11 billion
Forecast Year [2030] USD 36.06 billion
CAGR (%) 9.24%

Pioneering Evolution in Biopharmaceutical Contract Manufacturing to Unlock Next Generation Therapeutic Development and Supply Chain Excellence

The contract manufacturing landscape for biopharmaceuticals has evolved from a supplementary service model to a strategic enabler of innovation and speed to market. As therapeutic modalities grow increasingly complex, from monoclonal antibodies to advanced cell and gene therapies, outsourcing partners are no longer mere service providers but critical collaborators in formulation, process optimization, and regulatory compliance. This transformation has been driven by the convergence of advanced technology platforms, stringent quality requirements, and a rising demand for operational flexibility across the development continuum.

Leading biopharmaceutical developers are leveraging partnerships to navigate the intricate balance between cost pressures and the imperative for high-quality output. The reliance on specialized analytical and quality control testing has intensified, while end-to-end biologics manufacturing services have become central to scaling promising drug candidates. Process development and optimization efforts are now pursued in tandem with regulatory authorities to expedite clinical transitions without compromising safety or efficacy.

Against this backdrop, contract manufacturing organizations are positioning themselves as full-spectrum partners capable of supporting both early-stage clinical objectives and high-volume commercial supply. This introduction lays the groundwork for understanding the strategic imperatives shaping the industry and sets the stage for examining the key forces, segmentation insights, and recommendations that follow.

Shifting Paradigms in Biopharmaceutical Contract Manufacturing as Technological Advances and Strategic Collaborations Drive Unprecedented Industry Transformation

The biopharmaceutical contract manufacturing sector is experiencing a profound shift catalyzed by technological breakthroughs, strategic alliances, and changing regulatory paradigms. Single-use technologies and continuous manufacturing approaches are replacing legacy stainless-steel systems, lending agility to production lines and reducing turnaround times. Artificial intelligence and advanced analytics are being integrated into quality control workflows to enhance predictive maintenance and ensure batch consistency.

These advancements coincide with a trend toward personalized medicine, prompting contract manufacturers to develop modular facility designs capable of handling small-batch, high-complexity products alongside traditional biologics. Partnerships between emerging cell and gene therapy innovators and established contract organizations are proliferating, driven by a mutual need for specialized expertise in vector production and cryopreservation protocols.

Simultaneously, regulatory bodies across major markets are issuing guidance that emphasizes process transparency and real-time monitoring. This regulatory evolution has spurred contract providers to adopt digital platforms that facilitate data integrity and compliance tracking. Consequently, the landscape is no longer defined solely by capacity but by the ability to deliver quality outcomes, accelerate timelines, and co-innovate with development partners.

Evaluating the Comprehensive Consequences of the 2025 United States Tariffs on the Biopharmaceutical Contract Manufacturing Supply Chain and Industry Dynamics

The introduction of new United States tariffs in 2025 has generated a ripple effect across the global supply chain for biopharmaceutical contract manufacturing. Raw materials and critical reagents imported from impacted regions are subject to increased duties, leading to elevated input costs and exerting pressure on margin structures. Contract manufacturing organizations have responded by reevaluating supplier portfolios, exploring nearshoring options, and renegotiating long-term supply agreements to buffer against volatility.

Smaller biotechnology firms, which often depend on specialized laboratory reagents and single-use components sourced abroad, find themselves particularly exposed to these cumulative duties. In contrast, larger organizations with diversified supplier networks and in-house formulation capabilities are better positioned to absorb or mitigate the cost burden. Nevertheless, both cohorts are experiencing longer lead times and heightened logistical complexity, underscoring the importance of supply chain resilience.

To alleviate the impact of tariff-driven cost increases, outsourced manufacturing partners are prioritizing process intensification and yield enhancement strategies. By optimizing upstream cell culture conditions and refining downstream purification steps, contract providers can reduce overall material consumption and partially offset higher procurement costs. These measures, combined with strategic inventory management, are essential for maintaining competitiveness in an environment shaped by trade policy shifts.

Revealing Segmentation Insights in Biopharmaceutical Contract Manufacturing across Service and Product Types Production Stages Applications and Organisation Sizes

A granular examination of service type, product type, production stage, application, and organisation size reveals nuanced opportunities and challenges within the contract manufacturing domain. Analytical and quality control testing remains foundational, with emerging emphasis on high-throughput, multi-attribute methods that accelerate decision making. Biologics manufacturing services are evolving to support increasingly complex molecules, while process development and optimization initiatives are being structured as parallel workstreams, enabling faster transitions from bench scale to pilot production.

On the product front, cell and gene therapies demand specialized vector production capabilities, encompassing CAR T therapy workflows and precise gene editing protocols. Monoclonal antibodies continue to benefit from well-established platform processes, whereas recombinant proteins, including enzymes and hormones, leverage optimized expression systems to achieve high yields. Vaccines represent another dynamic segment, with mRNA constructs, protein subunit platforms, and viral vector approaches each requiring distinct manufacturing know-how.

Across clinical and commercial production stages, the industry demonstrates divergent priorities. Phase I through Phase III clinical batches focus on agility and regulatory alignment, whereas commercial manufacturing emphasizes cost efficiencies and scale. Therapeutic applications span autoimmune disorders, cardiovascular diseases, infectious diseases with bacterial, parasitic, and viral strains, neurology, and oncology, each presenting unique quality and safety considerations. Finally, large organisations seek full-service partnerships for end-to-end supply security, while small and medium enterprises often prioritize flexible, project-based engagements to support innovation without heavy capital investment.

Uncovering Regional Dynamics in Biopharmaceutical Contract Manufacturing Spanning the Americas Europe Middle East Africa and Asia Pacific Markets

Regional dynamics play a pivotal role in shaping outsourcing strategies and cost structures. The Americas continue to command significant contract manufacturing capacity, supported by a robust ecosystem of CMOs, regulatory expertise, and established logistics networks. Conversely, Europe, Middle East & Africa benefit from a rich pool of specialized scientific talent, favorable tax incentives in select markets, and a strong tradition of academic-industry collaborations that fuel early-stage bioprocess innovation.

Asia-Pacific has emerged as a growth epicenter, propelled by manufacturing cost arbitrage, government-backed infrastructure investments, and a burgeoning domestic pipeline of biotechnology ventures. Contract providers in this region are expanding capacity to accommodate global demand, introducing state-of-the-art aseptic filling suites and advanced analytics platforms. Simultaneously, regional regulatory authorities are harmonizing standards with international guidelines, simplifying cross-border transfers and bolstering global supply chain integration.

This geographic tapestry underscores the need to align outsourcing decisions with regional strengths. Manufacturing in North America may offer shorter lead times and streamlined regulatory pathways, while partnerships in Europe, Middle East & Africa grant access to specialized services and collaborative research frameworks. Meanwhile, Asia-Pacific is carving out a dual role as both a cost-competitive production hub and a fast-growing market for biologic products, reshaping global capacity dynamics.

Identifying Leading Innovators and Strategic Collaborators Shaping the Future of Biopharmaceutical Contract Manufacturing Worldwide

Leading contract manufacturing organizations have distinguished themselves through technological leadership, capacity footprint, and strategic alliances with both large biopharmaceutical firms and emerging biotech innovators. Several providers have invested heavily in single-use bioreactor systems and continuous chromatography, while others have enhanced their analytical testing suites with multi-attribute mass spectrometry and automated sampling technologies.

Strategic collaborations between CMO partners and academic institutions have accelerated the translation of novel modalities such as gene-edited cell therapies, enabling seamless technology transfer and risk-sharing models. Service providers with modular facility designs offer cost-efficient options for early-stage developers, while those operating mega-scale commercial sites cater to high-volume monoclonal antibody and vaccine production. Additionally, partnerships with reagent manufacturers and equipment suppliers have strengthened supply chain resilience and fostered co-innovation.

The competitive landscape is further shaped by the pursuit of sustainability credentials, with top companies adopting green chemistry principles, carbon-neutral facility operations, and circular single-use plastics recycling programs. These strategic differentiators enhance brand reputation and meet the rising expectations of stakeholders seeking environmentally responsible outsourcing partners.

Actionable Strategies for Industry Leaders to Drive Growth and Operational Excellence in the Evolving Biopharmaceutical Contract Manufacturing Landscape

Industry leaders must adopt a multi-pronged approach to secure resilience and drive growth. Investing in digital platforms that integrate real-time process monitoring with predictive analytics will sharpen decision making and reduce batch failure risks. Flexible manufacturing networks, combining modular facilities and single-use technologies, offer the agility needed to address fluctuating demand profiles across clinical phases and therapeutic modalities.

Formulating collaborative frameworks that incentivize joint process development and shared risk can accelerate time-to-clinic and optimize capital allocation. Leaders should also explore strategic alliances that extend beyond capacity, encompassing co-development partnerships, reagent co-investment, and joint intellectual property arrangements. Diversifying supply chains through geographic dispersion will mitigate tariff impacts and logistical disruptions.

Equally vital is cultivating talent with cross-functional expertise in bioprocess engineering, data science, and regulatory affairs. By fostering a culture that values continuous improvement and open innovation, organizations can maintain operational excellence while adapting to evolving market demands. Embracing sustainability initiatives will further differentiate service offerings and align with corporate social responsibility objectives, ensuring long-term stakeholder value creation.

Methodological Rigor and Innovative Research Techniques Employed to Uncover Critical Insights in Biopharmaceutical Contract Manufacturing Studies

This analysis is grounded in a hybrid research methodology that blends rigorous secondary research with primary qualitative interviews. An extensive review of regulatory guidelines, industry white papers, and proprietary company publications provided the foundational understanding of technological trends and policy shifts. Secondary data sources were vetted for credibility and cross-referenced against recent peer-reviewed journals to ensure factual accuracy.

Complementing this desk research, structured interviews were conducted with C-suite executives, process engineers, regulatory experts, and supply chain managers. These engagements offered nuanced perspectives on strategic imperatives, operational bottlenecks, and partnership models. Triangulation of quantitative and qualitative inputs enabled the identification of high-impact trends and actionable insights.

Key findings were further validated through a collaborative workshop with industry practitioners, where preliminary conclusions were stress-tested against real-world scenarios. This iterative approach ensured that recommendations are both grounded in empirical evidence and aligned with the strategic priorities of today's biopharmaceutical developers and contract manufacturing providers.

Summarizing Key Findings and Synthesizing Insights to Guide Strategic Decision Makers in the Biopharmaceutical Contract Manufacturing Ecosystem

In synthesizing the findings, several core themes emerge: the rising importance of technological agility, the critical role of strategic partnerships, and the necessity of supply chain resilience amid shifting trade policies. These insights underline the imperative for contract manufacturing organizations to transcend traditional capacity-only models and evolve into integrated innovation partners.

Segmentation analysis highlights that while monoclonal antibodies and recombinant proteins maintain established manufacturing platforms, cell and gene therapies and novel vaccine modalities demand bespoke process development expertise. Regional dynamics signal that Asia-Pacific is poised for rapid expansion, whereas Europe, Middle East & Africa will continue to offer strategic centers of excellence in early-stage development.

For decision makers, the convergence of digitalization, sustainability demands, and evolving tariff landscapes mandates a holistic strategy. By aligning service portfolios with emerging product trends, diversifying geographic footprints, and investing in cutting-edge process technologies, organizations can position themselves for long-term success. The insights presented serve as a blueprint for navigating the next chapter of biopharmaceutical contract manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid expansion of single-use bioreactor technologies in CDMO facilities to increase biopharmaceutical production flexibility
  • 5.2. Surging contract manufacturing demand for mRNA vaccines driving CDMO capacity investments across regions
  • 5.3. Integration of continuous manufacturing processes for monoclonal antibodies to enhance production efficiency
  • 5.4. Adoption of advanced analytics and artificial intelligence for predictive process optimization in biopharma CDMOs
  • 5.5. Strategic partnerships between biotech firms and CDMOs to accelerate cell and gene therapy manufacturing readiness
  • 5.6. Expansion of contract fill-finish services for high-potency and sterile biologics to meet evolving regulatory demands
  • 5.7. Growing interest in outsourcing viral vector production to specialized CDMOs to support gene therapy pipelines

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biopharmaceuticals Contract Manufacturing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Analytical & Quality Control Testing
  • 8.3. Biologics Manufacturing Service
  • 8.4. Process Development & Optimization

9. Biopharmaceuticals Contract Manufacturing Market, by Product Type

  • 9.1. Introduction
  • 9.2. Cell And Gene Therapy
    • 9.2.1. CAR T Therapy
    • 9.2.2. Gene Editing Therapy
  • 9.3. Monoclonal Antibodies
  • 9.4. Recombinant Proteins
    • 9.4.1. Enzymes
    • 9.4.2. Hormones
  • 9.5. Vaccines
    • 9.5.1. mRNA Vaccines
    • 9.5.2. Protein Subunit Vaccines
    • 9.5.3. Viral Vector Vaccines

10. Biopharmaceuticals Contract Manufacturing Market, by Production Stage

  • 10.1. Introduction
  • 10.2. Clinical
    • 10.2.1. Phase I
    • 10.2.2. Phase II
    • 10.2.3. Phase III
  • 10.3. Commercial

11. Biopharmaceuticals Contract Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Autoimmune Disorders
  • 11.3. Cardiovascular
  • 11.4. Infectious Diseases
    • 11.4.1. Bacterial
    • 11.4.2. Parasitic
    • 11.4.3. Viral
  • 11.5. Neurology
  • 11.6. Oncology

12. Biopharmaceuticals Contract Manufacturing Market, by Organisation Size

  • 12.1. Introduction
  • 12.2. Large Organisation
  • 12.3. Small & Medium Organisation

13. Americas Biopharmaceuticals Contract Manufacturing Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie, Inc.
    • 16.3.2. Ajinomoto Co., Inc.
    • 16.3.3. 3P Biopharmaceuticals
    • 16.3.4. Aenova Group GmbH
    • 16.3.5. AGC Biologics
    • 16.3.6. Aurobindo Pharma Limited
    • 16.3.7. Boehringer Ingelheim International GmbH
    • 16.3.8. Cambrex Corporation
    • 16.3.9. Catalent, Inc.
    • 16.3.10. Celonic AG
    • 16.3.11. FUJIFILM Diosynth Biotechnologies
    • 16.3.12. INCOG BioPharma Services, Inc.
    • 16.3.13. JRS PHARMA GmbH + Co. KG
    • 16.3.14. KBI Biopharma Inc
    • 16.3.15. Lonza AG
    • 16.3.16. Merck KGaA
    • 16.3.17. Pressure BioSciences, Inc. by Emergent Health Corp.
    • 16.3.18. ProBioGen AG
    • 16.3.19. Rentschler Biopharma SE
    • 16.3.20. Samsung Biologics
    • 16.3.21. Thermo Fisher Scientific Inc.
    • 16.3.22. Toyobo Co., Ltd.
    • 16.3.23. WuXi Biologics, Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHAI
  • FIGURE 26. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIOPH